clinical trial · NCT04684914
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
Hepatitis B, ChronicHepTcellPlacebo
brief summary
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
started
Dec 26, 2020
primary completion
Mar 27, 2024
completion
Apr 17, 2024
last updated
Dec 8, 2025
official title
Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol